Axsome Therapeutics, Inc. AXSM announced that the FDA has accepted its resubmitted new drug application (NDA) seeking approval for AXS-07 for the acute treatment of migraine.A final decision from the regulatory...
Stocks that traded heavily or had substantial price changes on Monday:
It will take a lot, but this goal isn't out of reach for these stocks.
Have investors already missed the boat with this stock?
Are these mid-cap stocks giants in the making?
Two mid-cap drugmakers stand out as logical targets for AbbVie.
How much longer can this biotech's run last?
Regulatory momentum, bullish Wall Street analysts and favorable technicals all suggest Krystal Biotech, Inc. may be a gem.
The company is moving quickly to market its newly approved therapy.
These "exciting" companies aren't for everyone.